Bluejay Diagnostics (NASDAQ:BJDX) CEO Indranil Dey Acquires 12,500 Shares

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) CEO Indranil Dey acquired 12,500 shares of the company’s stock in a transaction on Saturday, March 14th. The stock was acquired at an average cost of $2.00 per share, for a total transaction of $25,000.00. Following the completion of the acquisition, the chief executive officer owned 12,501 shares of the company’s stock, valued at $25,002. This trade represents a 1,250,000.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Bluejay Diagnostics Trading Up 3.0%

BJDX traded up $0.05 during trading on Monday, hitting $1.72. The company’s stock had a trading volume of 34,940 shares, compared to its average volume of 155,600. The business’s fifty day simple moving average is $1.90 and its 200 day simple moving average is $3.24. The firm has a market capitalization of $1.77 million, a price-to-earnings ratio of -0.15 and a beta of 0.72. Bluejay Diagnostics, Inc. has a twelve month low of $1.63 and a twelve month high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent SEC filing. Institutional investors own 18.47% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.